CATUG Bio and Biosion Announce Strategic Collaboration to Co-Develop mRNA-LNP Delivery Solutions for In Vivo CAR-T Therapies

Recently, Catug Biotechnology Co., Ltd. (hereinafter referred to as "Catug") and Bo sheng ji medicine science and technology (suzhou) co., LTD (hereinafter referred to as "Bo Sheng Ji") officially announced the signing of a strategic cooperation agreement, and the two parties will carry out mRNA-LNP delivery on a global scale.In vivoCutting-edge technology collaboration in (in vivo) CAR-T therapy aims to significantly reduce the production costs of traditional CAR-T therapies, enhance their accessibility, and benefit more patients. Representatives from both companies in attendance included Dr. Wang Xiao, co-founder and CEO of Catug Biotechnology Co., Ltd., and Dr. You Fengtao, Dean of the New Drug Research Institute at Bo Sheng Ji Medicine Science and Technology (Suzhou) Co., LTD.

In recent years, CAR-T therapy has gained significant attention due to its remarkable efficacy, becoming the "star therapy" in the field of cancer treatment. As of November 2023, there are 10 CAR-T therapies on the global market, four of which are available in China. The number of CAR-T clinical studies in China has exceeded 655, and the industry is developing rapidly. However, limited by the patient-specific production model, expensive raw materials such as viral delivery vectors, lengthy production processes, and high research and development costs, the price and production cycle of autologous CAR-T therapies remain high, severely limiting patient accessibility.

In vivo generation of CAR-T therapy via mRNA-LNP delivery of CAR has demonstrated exciting efficacy in animal models. The mRNA-LNP delivery technology, with its advantages in cost and safety, is expected to significantly reduce the cost and production cycle of CAR-T therapy. However, challenges such as LNP patent restrictions, immune cell targeting, control of high-dose mRNA immunogenicity, dose-response relationship studies, and large-scale GMP production remain urgent issues for the industry to address.

Catug Biotechnology and Bo Sheng Ji Medicine Science and Technology (Suzhou) Co., LTD, based on their understanding of the development of the mRNA and CAR-T industries, have proactively initiated research on In vivo CAR-T therapy mRNA solutions. The strategic cooperation between Catug Biotechnology and Bo Sheng Ji will further solidify their collaborative foundation, fully leverage the complementarity of their technologies, continuously overcome technical challenges, and jointly develop an integrated mRNA-LNP solution for In vivo CAR-T therapy.

AboutCatug

Catug Biotechnology Co., Ltd. is an innovative technology company focusing on the development and application of new biopharmaceutical technologies, with research and development centers and industrialization bases in both Suzhou and Wuhan. It aims to provide one-stop CRDMO services covering the entire industrial chain for gene and cell therapy drugs and nucleic acid drugs, from drug discovery, quality research, clinical applications, to industrialization. The core team of Catug comes from top international and domestic biotechnology companies as well as renowned universities and research institutions in and outside China, possessing extensive industrial technology and management experience in the fields of gene therapy and nucleic acid therapy. Starting with four core technological service platforms—high-quality large-scale plasmid process development and production, mRNA synthesis and delivery full-process development and production, and nucleic acid analytical methods and quality research—the company is committed to building a top-tier technological platform and becoming a model in the new generation of innovative biotechnology industries.

AboutBo Sheng Ji

Bo Sheng Ji Medicine Science and Technology (Suzhou) Co., LTD is a national high-tech enterprise primarily focused on the development of breakthrough tumor cell immunotherapy technologies and cell drug products. The company is committed to developing First-in-class and Best-in-class CAR-T cell drugs with internationally leading standards. It has established a nearly 10,000-square-meter fully automated CAR-T cell production base compliant with GMP standards, which is currently the leading fully automated CAR-T cell production base in the Asia-Pacific region, laying a solid foundation for the commercialization of CAR-T cells. Among its pipeline, several cell drug candidates targeting T-cell acute lymphoblastic leukemia/lymphoma and pediatric neuroblastoma have shown encouraging preliminary efficacy and safety in clinical validation. In the development of off-the-shelf cell products, Bo Sheng Ji has utilized γδT cells as a platform, with multiple CAR-γδT products demonstrating excellent in vivo efficacy and safety in preclinical studies. Additionally, beyond oncology indications, Bo Sheng Ji is actively expanding its product pipeline to address chronic conditions such as autoimmune diseases and aging-related diseases.